| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3905687 | Urology | 2006 | 6 Pages |
Abstract
We consider that HER-2 overexpression, as measured by immunohistochemistry, may be useful as a marker of an unfavorable prognosis by predicting the interval until relapse and outcome after endocrine therapy in patients with bone metastatic prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Yoshitaka Nishio, Yoshiaki Yamada, Hiroto Kokubo, Kogenta Nakamura, Shigeyuki Aoki, Tomohiro Taki, Nobuaki Honda, Atsuko Nakagawa, Shinsuke Saga, Kazuo Hara,